Please check your internet connection and try again.
# IV Hydrocortisone for Acute Asthma
## Overview
Intravenous (IV) hydrocortisone is a corticosteroid used as an adjunct in the management of moderate to severe acute asthma exacerbations when initial treatment with inhaled bronchodilators is insufficient. It works by reducing airway inflammation. Onset of action is typically delayed, with maximal benefit seen after several hours.
## Primary Indications
Adjunctive treatment for moderate to severe acute asthma exacerbations.
## Adult Dosing
* **Loading Dose:** 100 mg IV every 6 to 8 hours.
* **Maintenance Dose:** Often continued at 100 mg IV every 6 to 8 hours. Some protocols may transition to oral prednisone/prednisolone once the patient can tolerate oral intake and shows clinical improvement.
## Pediatric Dosing
* Dosing can vary significantly by age and weight.
* **Commonly Recommended:** 5 mg/kg IV every 6 to 8 hours.
* **Maximum Dose:** Typically capped at 200 mg per dose, though some protocols may allow up to 100 mg per dose depending on institution.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment recommended, but monitor for adverse effects.
* **Hepatic Impairment:** No specific dose adjustment recommended, but monitor for adverse effects.
## Contraindications
* Known hypersensitivity to hydrocortisone or its components.
* Systemic fungal infections.
* Use in acute asthma is generally not contraindicated by comorbid conditions, but caution is advised in patients with certain infections or recent live vaccinations.
## Adverse Effects
* **Short-term:** Hyperglycemia, fluid retention, electrolyte disturbances (hypokalemia), mood changes, insomnia, increased susceptibility to infection.
* **Long-term (less common with short-term IV use):** Adrenal suppression, Cushingoid effects, osteoporosis, impaired wound healing, peptic ulceration, cataracts, glaucoma.
## Key Drug Interactions
* **CYP3A4 Inducers** (e.g., rifampin, phenytoin, carbamazepine): May decrease hydrocortisone levels.
* **CYP3A4 Inhibitors** (e.g., ketoconazole, macrolides): May increase hydrocortisone levels.
* **Diuretics** (non-potassium-sparing): Increased risk of hypokalemia.
* **Vaccines:** Live vaccines should be avoided during treatment due to reduced immune response and increased risk of disseminated infection.
## Monitoring
* Blood glucose levels, especially in diabetic patients.
* Electrolytes (potassium).
* Signs of infection.
* Clinical response to asthma therapy (respiratory rate, wheezing, oxygen saturation).
* Signs of Cushingoid effects with prolonged use.
## Clinical Pearls
* IV hydrocortisone is typically used when patients cannot tolerate oral medications or require rapid systemic corticosteroid delivery.
* It is not a rescue medication for immediate bronchodilation; inhaled short-acting beta-agonists remain the first-line treatment.
* The benefit of IV hydrocortisone in asthma is not immediate and may take several hours to become apparent.
* Transitioning to oral corticosteroids (e.g., prednisone, prednisolone) is usually recommended once clinical improvement is achieved and the patient can take oral medications.
* Ensure adequate fluid and electrolyte balance.
***
*Disclaimer: This information is intended for clinical use and does not substitute for professional medical judgment. Always consult the most current prescribing information and institutional protocols before administering any medication.*
